American Oncology Network & Sarah Cannon Research Institute Announce Cancer Research Collaboration Fort Myers, Fla. & Nashville, Tenn., June 15, 2020 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON), and Sarah Cannon Research Institute (Sarah Cannon) announced today a collaboration to...

Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...

CicloMed Announces First Patient Dosed with Ciclopirox Prodrug in Phase I Trial in Patients with Advanced Solid Tumors KANSAS CITY, Mo., Feb. 28, 2018 (GLOBE NEWSWIRE) -- CicloMed LLC, a biotechnology company developing novel treatments for bladder cancer, today announced that the first patient has been dosed in a...